Beijing Jiuneng Tianyuan Technology

Beijing Jiuneng Tianyuan Technology Co., Ltd. is a national high-tech pharmaceutical enterprise based in Beijing, China, specializing in the research, development, manufacturing, and sales of pharmaceuticals and health products. The company's core commercial portfolio includes Lidocaine Hydrochloride Injection, a national centralized procurement winning product used for local anesthesia, and Nicergoline Tablets, which were approved in 2025 to treat cognitive and memory deficits associated with cerebrovascular diseases and vascular dementia. Additionally, the company is developing an innovative formulation of Phloroglucinol freeze-dried orally disintegrating tablets using freeze-drying flash-release technology to target acute spasmodic pain. Beijing Jiuneng Tianyuan Technology collaborates with major domestic pharmaceutical manufacturers and research institutions to advance its integrated technology translation and product commercialization.